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In recent years, Raman spectroscopy has enjoyed a
strong resurgence in popularity due to advances in
the technology, which gives higher sensitivity, ease
of use and lower-cost instruments. In particular, it
has been finding application as a technique for
routine and non-routine analysis within a regulated
pharmaceutical environment. Many different
techniques are already utilised by the pharmaceutical
industry, including infrared (IR) spectroscopy,
nuclear magnetic resonance (NMR), X-ray
diffraction (XRD), high-performance liquid
chromatography (HPLC) and thermal methods.
Indeed, many of these techniques have been
developed in order to offer automated analyses.
However, it is now evident that Raman spectroscopy
is uniquely placed to support the growing demands
of the pharmaceutical industry, especially in relation
to high-throughput screening (HTS), rapid analyses,
non-invasive analyses (through sample vials and
packaging), no sample preparation and ease of use.
The ‘Raman effect’ involves inelastic scattering of
light – the radiation scattered by molecules is shifted
to a different frequency (energy) than the incident
radiation. This inelastic scattering was first predicted
in 1923 by A Smekal1, however it wasn’t until 1928
that Sir C V Raman carried out the first
experiments2, which confirmed the prediction and
led to the award of his Nobel prize in 1930. It
received considerable attention as a method of non-
destructive chemical analysis in the years following its
initial discovery, however this interest eventually
waned due to advances in IR spectroscopy. The
current renaissance in Raman has been driven by
advances in the photonics sector, most notably by the
introduction of lasers in the 1960s. More recently,
multichannel detectors (initially photodiode arrays
(PDAs), but now charge-coupled detectors (CCDs)
designed specifically for spectroscopy), more
advanced laser sources and high-performance optical
filters and spectrographs are all allowing the
development of ever more sensitive and reliable
Raman instruments. This process of innovation and
improvement has pushed backed the boundaries and
allowed Raman spectroscopy to become a powerful
analytical tool that can be accessed by specialists and
non-specialists alike. The technique has always had
the potential to find wide application in the
pharmaceutical industry but it is only now that the
instrumentation has evolved to the stage where its
potential can be realised. 
Wha t  i s  R aman ?
Raman spectroscopy is based on detection of light
that has been scattered inelastically by a sample (the
‘Raman effect’). This article will concentrate on the
vibrational data these measurements can give; the
overwhelming majority of studies and applications of
the technique are vibrational Raman experiments. 
In general, when light interacts with a substance it
does so in three main ways: the light may be
absorbed; it may be transmitted through the sample
unchanged; or it may be scattered. Figure 1 illustrates
the general principle of the measurement, which is
that the light from a powerful monochromatic light
source (invariably a laser) is focused onto the sample
of interest and as many as possible of the photons that
scatter from the sample are collected and dispersed in
a spectrometer. The photons that are scattered
elastically (i.e. with no change in their wavelength)
comprise the Rayleigh scattering, which is intense
but carries no vibrational information and so is
filtered out of the signal. In addition to the Rayleigh
scattering, Raman scattering, in which the frequency
of the incident photons changes due to interaction
with the sample, can also be detected. Unfortunately,
the Raman scattering comprises a very small fraction
of the incident photons, typically 0.0001%, hence the
need for an intense source and sensitive detector. 
Not all Raman-scattered photons have the same
change in energy. Some photons lose part of their
energy to give Stokes scattering, while others gain
energy and generate the anti-Stokes signal. To
generate an anti-Stokes signal, photons must
encounter a vibrationally excited molecule in the
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sample; Stokes scattering has no such requirement so
Stokes signals tend to be stronger than anti-Stokes and
spectra are normally recorded only on the Stokes
(energy loss) side of the spectrum. Stokes photons lose
energy by depositing it into vibrational excitation of
the sample so that the pattern of energy loss reflects
the vibrational levels within the sample. In practice,
plotting the intensity of Raman-scattered photons
against frequency difference between incident and
scattered radiation maps the vibrational spectrum of
the sample. Overall, Raman and IR signals measure
the same vibrational levels (with subtly different
selection rules), but the major difference is that the
presence of a vibrational band is detected in IR
measurements directly by the absorption of an IR
photon, while in Raman experiments the same
vibration causes the scattering of a photon, which
retains most of its energy but shows a small loss
corresponding to the same energy absorption by the
sample as occurs in IR spectroscopy.
Every compound has its own unique Raman
spectrum that can be used for both sample
identification and quantification. Raman and IR
spectroscopy can be used as complementary
techniques because, due to differences in the
spectroscopic selection rules, each is sensitive to
different components of a given sample. For
example, IR spectroscopy is generally more sensitive
to polar bonds such as O-H stretches, whereas
Raman is much more sensitive to vibrations of
carbon backbone structures and symmetrical bonds,
such as C = C groups. Using both techniques to
characterise a particular substance can provide twice
as much information on its chemical composition as
that obtained by using either technique on its own.
Given that inexpensive Fourier-transform (FT) IR
absorption spectrometers are widely available, the
advantages of Raman spectroscopy would need to be
significant to justify changeover. There are indeed
many advantages, the most notable being:
• no sample preparation is required – Nujol or KBr
matrices are not used; the laser is simply directed
onto the sample; 
• wet samples or even aqueous solutions can be
analysed because water is a particularly poor
Raman scatterer;
• in situ analysis is straightforward with no sample
preparation required – Raman can even analyse
samples through glass and plastic;
• fibre optics up to hundreds of metres in length can
be used for remote analysis;
• Raman bands are narrower than those typically
observed in mid-IR spectra and can be used more
readily for quantitative analysis;
• the technique is suitable for use with both organic
and inorganic materials;
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• Raman spectroscopy can measure vibrations from
symmetrical molecular modes, which are
frequently very weak in IR spectra; and
• Raman bands can be related more easily to
chemical structure due to the fact that
fundamental modes are measured.
Most of the disadvantages of Raman methods arise
directly from the fact that it is a weak effect, which
leads to the need for intense laser excitation sources
and sensitive detectors. In the past, this, in turn, led
to relatively high costs for Raman instrumentation,
which was one of the main obstacles to the
widespread application of Raman spectroscopy for
routine chemical and biological analyses. However,
this situation is now changing, as laser and detector
costs have fallen significantly, while their
performance has improved steadily. 
There are numerous variations on general
experimental Raman methodology but the most
commonly encountered variants are dispersive and
FT Raman methods. In general, Raman instruments,
whether interferometric (FT) or dispersive are
constructed of three basic components: the laser
excitation source; the spectrometer (or energy
analyser); and the detector. FT-Raman typically
employs a 1,064nm excitation laser, an inferometer
(which encodes the unique frequencies of the
Raman spectrum into a single scan) and a single-
channel near-infrared (NIR) detector. In
comparison, dispersive systems use visible or near-
infrared excitation lasers (488, 532, 633 and ca.
785nm are employed most commonly), a grating for
dispersion and a multichannel CCD detector.
Overall, the dispersive systems are much more
sensitive than those based on 1,064nm
laser/inferometer combinations, primarily because of
the exceptional quantum efficiency of modern CCD
detectors and the enhancement in Raman signal that
occurs at shorter wavelengths. This increased
sensitivity allows data to be acquired over shorter
time periods, which has significant implications for
HTS applications. The dispersive instruments are also
less expensive than FT instruments. 
A significant factor in considering any Raman
experiment on unpurified samples is the possibility
that the sample may give a broad optical emission
signal. In Raman spectroscopy, such background
fluorescence is problematic because the Raman signal
is relatively weak, so any other emission coming
from the sample can drown it out. Problem levels of
background fluorescence can arise not only from
samples that contain known flurorophores, but also
from adventitious fluorescent impurities that may be
present at relatively low (sub-millimolar)
concentrations. The problem of sample
luminescence has been recognised for a considerable
time and many different strategies have been
employed, with reasonable success, to overcome it.
These include quenching the luminescence by using
surface-enhanced Raman spectroscopy (SERS) and
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shifting the excitation wavelength to one that does
not generate luminescence or gives luminescence
that lies at a different wavelength range to the
Raman signal3. Until the 1990s, the only widely
available technique was FT Raman, which utilised
long excitation sources and therefore did not excite
the fluorescence that was observed when using
visible excitation. Recently, dispersive instruments,
such as the example given in Figure 2, with long
wavelength (NIR) excitation have begun to find
favour as a compromise, which reduces sample
fluorescence in much the same way as FT
instruments, but gives the sensitivity advantages
inherent with multichannel CCD detection.
Typically, these use ca. 785nm excitation and a
classical spectrograph, although the advantages of
using an echelle spectrograph, which allows the
entire useful spectral range to be recorded at high
resolution with no moving parts, are now being
recognised and exploited.
The final major choice to be made in specifying a
Raman spectrometer is whether to opt for a
microscope-based system or use ‘macroscopic’
sampling. A wide range of commercial instruments
based on both sampling protocols is available and the
choice of a microscope-based system is easy if
sampling of very small (<10µm diameter) is required.
If this is not the case, the choice is much more
complex as it is necessary to balance the increased cost
and complexity of a microscope-based system (with its
potential for sample damage from the highly focused
laser source) against typical macroscopic systems,
which are simpler, more rugged and less costly and
allow sampling of regions ca. 100–200µm diameter.
This macroscopic sampling is clearly a technique that
has application for HTS, allowing the user to sample
from a larger area and providing additional assurance,
especially if the samples are inhomogeneous. Clearly,
there is no single best option that would satisfy all
users; individual requirements are likely to determine
the optimum choice.
R aman  S p e c t r o s c o p y  i n  t h e
P h a rma c e u t i c a l  I n d u s t r y
Raman spectroscopy has been applied successfully in
the study of various drugs, including pharmaceuticals4,
narcotics5 and drug delivery devices6,12. Historically,
visible Raman spectroscopy did not find application
within the pharmaceutical industry due to the
problems associated with fluorescence and
photodegradation. FT-Raman yielded spectra outside
the fluorescent region, although this technique
required high laser power, which often resulted in
sample decomposition. The use of dispersive Raman
did, however, offer an excellent compromise to these
problems and has found increased utility in this area.
The implementation of swift and safe drug
development processes is clearly a priority for the
pharmaceutical industry. With current technology
unable to match the pace of drug discovery and
design, there is an obvious need to address this
bottleneck and provide innovative new technology
to improve and accelerate drug discovery. Already,
the use of robotics, HTS and advanced software and
computers has transformed the industry. However,
there will always be a need to improve the efficiency
of such systems and drive costs downwards. The
development of analytical techniques that push back
the boundaries is therefore critical and should be
implemented to improve quality, offer additional
assurance, increase efficiency and reduce cost. 
Raman spectroscopy is uniquely placed to support
the growing demands of the pharmaceutical industry,
especially in relation to HTS, rapid analyses
(sometimes less than one second per sample) and
non-invasive analyses (through sample vials and
packaging) – all without the need for sample
preparation. Many different techniques are already
utilised by the pharmaceutical industry, including IR
spectroscopy, NMR, XRD, high-performance
liquid chromatography (HPLC) and thermal
methods. Indeed, many of these techniques have
been developed in order to offer automated analyses.
However, Raman spectroscopy offers a range of
significant advantages over these techniques and has
been applied in the investigation of pharmaceutical
samples, including:
• rapid identification of raw materials;
• analysis of drug mixtures, APIs and excipients;
• identification of contaminants in samples;
• characterisation of formulated materials; and
• process monitoring.
In particular, Raman has found application in the
analysis of polymorphs (compounds with more than
one crystalline form)7. Compounds often exist as
more than one polymorph so the properties and,
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importantly, the stability and reactivity of the drug
will be largely influenced by the existence of these
polymorphs. If more than one polymorph exists, the
Raman spectra will differ, usually quite significantly.
In addition, Raman can also be used to distinguish
between pseudo-polymorphs, where the degree of
hydration differs. Not only does Raman provide a
rapid method for the analysis of different
polymorphs, it also allows the work to be carried out
without additional sample preparation and is non-
contact. IR spectroscopy usually requires grinding of
the sample to form a mull or preparation of a KBr
pellet, which may influence the crystalline form of
the sample. Also, techniques such as XRD and DSC
take much longer when compared with Raman
analyses. Hence, Raman provides a unique platform
to discriminate between different polymorphs,
which is more rapid, flexible and robust than
existing analytical techniques. 
Tetracaine gels are another example of the efficacy of
Raman spectroscopy for drug monitoring or analysis.
Tetracaine, in an aqueous gel, provides an effective
percutaneous anaesthesia of intact healthy skin and has
found useful application in a bioadhesive transdermal
patch6. Its effectiveness is due to a low melting point
metastable hydrate in aqueous media. Drug delivery
involves Tetracaine undergoing a phase change from a
solid to an oily suspension at skin temperature12. The
function of Tetracaine is to diffuse through the outer
layers of the skin and desensitise the nociceptors
within the epidermis. Figure 3(a) shows Raman spectra
for Tetracaine after various periods of exposure to
skin. An appropriate internal standard (rutile-TiO2)
was introduced into the sample in order to determine
the absolute concentration of the Tetracaine. A
decrease in the Tetracaine band intensity over time
with no change in TiO2 band intensity indicated a
drop in the Tetracaine concentration as shown in
Figure 3(b). The clinical applications of Tetracaine
include painless venepuncture and miscellaneous
topical surgical procedures. 
Despite the success of Raman methods in analysing
bulk materials, investigations involving very low
concentrations were prohibited by the low sensitivity of
normal Raman methods. However, the development
of SERS, which involves the analysis of samples that
have been adsorbed to, or interact with, metal surfaces
(typically a roughened metal electrode or a metal
colloid) has allowed trace analysis by Raman methods
to be carried out8,9. Under optimised conditions, SERS
can provide spectral enhancements of 1014 or even 1015
compared with normal Raman scattering10. For
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example, it can be used for HTS and detection of low
concentrations of drug compounds11. 
These are only a few examples of how Raman
spectroscopy can be exploited for the analysis of
pharmaceuticals. However, what is clear from this
work is that Raman has now become a very
important and powerful analytical tool. Its utility
within the pharmaceutical sector is now of particular
significance, because it can provide selective, rapid
HTS and highly sensitive methods of analysis, which
are low cost, non-contact and do not require any
time-consuming sample preparation of the type that
exists with many of the current analytical techniques
available. It has evolved in the last decade from a
complex research tool to a fairly user-friendly
technique that is for everyday use.
Raman spectroscopy has the potential to play a key
role in the pharmaceutical industry and allow a more
streamlined approach to drug development.
Undoubtedly, it will have a positive impact in this
area in the coming years, with the capacity to be used
throughout the drug development life-cycle. ■
B U S I N E S S  B R I E F I N G :  F U T U R E  D R U G  D I S C O V E R Y
6
Technology & Services
11. S E J Bell and S J Spence, Analyst, 126, 2001, pp. 1–3.
12. A D Woolfson and D F McCafferty, Int. J. Pharm., 94, 1993, pp. 75–80.
Contact Information
Avalon Instruments Ltd 
97 Botanic Avenue, Belfast, BT7 1JN 
Northern Ireland, UK
Tel: +44 (0)28 9043 9555 
Fax: +44 (0)28 9043 9646 
e-Mail: a.boyd@avaloninst.com 
Web: http://www.avaloninst.com
